[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367709-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367709-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","statins-and-the-risk-of-gynecological-cancer-a-norwegian-population-based-cohort-study","Statins and the risk of gynecological cancer - a Norwegian population-based cohort study","","Endometrial, ovarian, and cervical cancers cause substantial mortality worldwide, yet the relationship between statin use and gynecological cancer risk remains uncertain. A population-based cohort study followed Norwegian women aged 50+ from 2004 to 2018 using Prescription Database and Cancer Registry data. Cox models assessed overall and by-type (lipophilic vs hydrophilic) statin use, including subgroup analyses by age and histology. Statins showed reduced endometrial cancer risk, limited to lipophilic use, with no consistent ovarian or cervical associations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/statins-and-the-risk-of-gynecological-cancer-a-norwegian-population-based-cohort-study/367709/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/statins-and-the-risk-of-gynecological-cancer-a-norwegian-population-based-cohort-study/367709.png","ImageObject",300,407,{"name":42,"@type":43},"McQueen","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What cancers were examined in this study?","Question",{"text":63,"@type":64},"The study evaluated endometrial, ovarian, and cervical cancers overall and in subgroups defined by statin type and other factors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was statin exposure assessed?",{"text":68,"@type":64},"Statin use was examined overall and by type (lipophilic vs hydrophilic), and analyses considered cumulative defined daily doses and time since cessation for each cancer type.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings about cancer risk?",{"text":72,"@type":64},"Statin use was associated with a reduced risk of endometrial cancer, with associations observed only for lipophilic statins. No consistent associations were found for ovarian or cervical cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367709,1790676447,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original article  \nStatins and the risk of gynecological cancer: a Norwegian population-based cohort study  \nLeif Lukas L€ofling 1,2, Nathalie C. Støer 1, Edoardo Botteri 1,3, Rene Turzanski Fortner 1,4, 􀀃  1 Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway  \n2Section for Epidemiology, Norwegian Veterinary Institute, Ås, Norway  \n3Section for Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway 4 Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany  \n􀀃 Corresponding author. Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.  \nE-mail: [r.fortner@dkfz.de](r.fortner@dkfz.de).  \nAbstract  \nBackground: Endometrial, ovarian, and cervical cancers are the most common gynecological cancers, with 1.4 million diagnoses worldwide in 2022. Statins are widely used for cardiovascular conditions and have been studied for their association with gynecological cancer risk, but results to date have been inconclusive.  \nMethods: We conducted a population-based cohort study including data from the Norwegian Prescription Database and the Cancer Registry of Norway, and followed women aged ≥50 years from 2004 to 2018. We examined the association between statin use overall and by type (lipophilic, hydrophilic), and the risk of endometrial, ovarian, and cervical cancers overall and by age groups and histologic subgroup using Cox proportional hazard models.  \nResults: The cohort study included 1 083 629 women. During a median follow-up of 11.6 years, 334 582 (31%) used statins at least once. There were 7709 cases of endometrial, 4415 cases of ovarian, and 1603 cases of cervical cancers. Statin use was associated with reduced risk of endometrial cancer [current use hazard ratio (HR) ¼ 0.90, 95% confidence interval (CI): 0.85–0.96; past use HR ¼ 0.79, 95% CI: 0.71–0.88]; associations were observed only for the lipophilic statins, and with similar associations by age groups and for type I and II endometrial cancer. No consistent associations were found for ovarian or cervical cancers. We found no trends for cumulative defined daily doses of current use or time since cessation for any cancer type.  \nConclusion: Statin use was associated with a reduced risk of endometrial cancer but not with the risk of ovarian cancer or cervical cancer.  \nKeywords: gynecological cancers; statins; risk; population-based; cohort.  \nKey Messages  \n􀀏 We evaluated whether statins are associated with the risk of cancers of the endometrium, ovary, and cervix, both overall and within subgroups defined by type of statin, strength of statin, age, histology, and body mass index.  \n􀀏 Statin use was associated with reduced risk of endometrial cancer, with associations observed only for the lipophilic statins, and with similar associations by age groups and for type I and II endometrial cancer. No consistent associations were found for ovarian or cervical cancers.  \n􀀏 The robust inverse associations observed for endometrial cancer, evident across various subgroups defined by individual characteristics (e.g. age, body mass index) and tumor histology, suggest that statins represent a class of drugs that may have promise as non-cancer drugs that could be re-purposed for endometrial cancer prevention.  \nIntroduction  \nEndometrial (EC), epithelial ovarian (EOC), and cervical cancers (CC) are among the most common cancers in females, and substantial causes of cancer-related mortality [1] .  \nStatins, widely used to treat and prevent cardiovascular diseases, inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase, leading to reduced cholesterol levels and inhibition of proteins involved in the development and progression of several cancers, including gynecological  \ncancers [2, 3] . Previous studies on statin use and gynecological cancer risk have reported conflicting results [3, 4] . Th","cbCaicx6JWQZZ7Ny","https://ap.wps.com/l/cbCaicx6JWQZZ7Ny","pdf",1401655,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Study design, population, and data sources\n# Results\n# Conclusion\n# Key Messages","[{\"question\":\"What cancers were examined in this study?\",\"answer\":\"The study evaluated endometrial, ovarian, and cervical cancers overall and in subgroups defined by statin type and other factors.\"},{\"question\":\"How was statin exposure assessed?\",\"answer\":\"Statin use was examined overall and by type (lipophilic vs hydrophilic), and analyses considered cumulative defined daily doses and time since cessation for each cancer type.\"},{\"question\":\"What were the main findings about cancer risk?\",\"answer\":\"Statin use was associated with a reduced risk of endometrial cancer, with associations observed only for lipophilic statins. No consistent associations were found for ovarian or cervical cancers.\"}]","Statins and the risk of gynecological cancer - a Norwegian population-based cohort study | PDF",1790172175]